Prognostic and therapeutic potential of copper-induced cell death-related lncRNAs in lung squamous cell carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.New biomarkers, copper-induced cell death-related long non-coding RNAs (lncRNAs), predict outcomes in lung squamous cell carcinoma (LUSC). A risk model stratifies patients, guiding personalized immunotherapy and targeted drug treatments for improved lung cancer care.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Lung squamous cell carcinoma (LUSC) presents significant treatment challenges due to poor prognosis and limited therapeutic avenues.
- Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development and progression.
Purpose Of The Study
- To identify and validate copper-induced cell death-related lncRNAs as prognostic markers in LUSC.
- To develop a risk stratification model for predicting patient outcomes and response to immunotherapy.
- To explore the therapeutic implications of identified lncRNAs for personalized treatment strategies in LUSC.
Main Methods
- Utilized The Cancer Genome Atlas (TCGA) database for LUSC patient data.
- Identified five key lncRNAs (AC010328.1, LINC01740, AL358613.2, MIR3945HG, AC002467.1) as independent prognostic markers.
- Developed a risk score model and Nomogram integrating lncRNA expression and clinical factors; performed survival, functional enrichment, tumor mutation burden, and immune dysfunction analyses.
Main Results
- A five-lncRNA signature effectively stratified LUSC patients into high- and low-risk groups with distinct overall survival.
- High-risk patients demonstrated increased immune evasion, poorer immunotherapy response, and sensitivity to targeted drugs (Quizartinib, Dasatinib).
- The developed Nomogram showed robust predictive accuracy for 1-, 3-, and 5-year survival outcomes in LUSC.
Conclusions
- Copper-induced cell death-related lncRNAs serve as novel, independent prognostic biomarkers for LUSC.
- The risk score model and Nomogram offer valuable tools for prognostic assessment and patient stratification.
- Findings provide actionable insights for optimizing immunotherapy and targeted therapy selection in LUSC management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...